Literature DB >> 29467493

c-Jun/AP-1 overexpression reprograms ERα signaling related to tamoxifen response in ERα-positive breast cancer.

Huan He1, Indranil Sinha1, Rongrong Fan1, Lars-Arne Haldosen1, Feifei Yan1, Chunyan Zhao2, Karin Dahlman-Wright1.   

Abstract

A critical mechanism that has been proposed for transcription regulation by estrogen receptor α (ER) is the tethering of ER to DNA via other transcription factors, such as AP-1. However, genome-wide assessment of the overlap in chromatin binding repertoires of these two transcription factors has not been reported. Here, we show that the AP-1 transcription factor c-Jun interacts with ER and that c-Jun chromatin binding shows extensive overlap with ER binding at the global level. Further, we show that c-Jun overexpression reprograms ER chromatin binding and modulates ER-mediated gene regulation. Our data are consistent with a mechanism where estrogen/ER-dependent crosstalk with AP-1 at the transcriptional level is mediated through the tethering of ER to DNA bound AP-1. Additionally, in our system c-Jun overexpression causes reduced sensitivity to tamoxifen in ER+ breast cancer cells. Integrated cistrome, transcriptome, and clinical data reveal TGFBI as a candidate gene which may confer tamoxifen resistance by ER and AP-1 crosstalk. Further, we show that TGFBI expression is elevated in breast cancer compared to normal breast. Together, our data provide a novel genome-wide footprint of ER and AP-1 crosstalk and suggest AP-1 and TGFBI signaling as potential therapeutic targets in AP-1-overexpressing ER-positive breast tumors.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29467493     DOI: 10.1038/s41388-018-0165-8

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  52 in total

1.  Altered pharmacology and distinct coactivator usage for estrogen receptor-dependent transcription through activating protein-1.

Authors:  Edwin Cheung; Mari Luz Acevedo; Philip A Cole; W Lee Kraus
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-10       Impact factor: 11.205

2.  FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.

Authors:  Mathieu Lupien; Jérôme Eeckhoute; Clifford A Meyer; Qianben Wang; Yong Zhang; Wei Li; Jason S Carroll; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2008-03-21       Impact factor: 41.582

Review 3.  Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development.

Authors:  Y T Ip; R J Davis
Journal:  Curr Opin Cell Biol       Date:  1998-04       Impact factor: 8.382

4.  Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.

Authors:  Tricia M Wright; Suzanne E Wardell; Jeff S Jasper; James P Stice; Rachid Safi; Erik R Nelson; Donald P McDonnell
Journal:  Mol Cancer Res       Date:  2014-08-06       Impact factor: 5.852

5.  Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer.

Authors:  Chunyan Zhao; Yichun Qiao; Philip Jonsson; Jian Wang; Li Xu; Pegah Rouhi; Indranil Sinha; Yihai Cao; Cecilia Williams; Karin Dahlman-Wright
Journal:  Cancer Res       Date:  2014-05-15       Impact factor: 12.701

6.  Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance.

Authors:  Mathieu Lupien; Clifford A Meyer; Shannon T Bailey; Jérôme Eeckhoute; Jennifer Cook; Thomas Westerling; Xiaoyang Zhang; Jason S Carroll; Daniel R Rhodes; X Shirley Liu; Myles Brown
Journal:  Genes Dev       Date:  2010-10-01       Impact factor: 11.361

7.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321

8.  Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.

Authors:  Say Li Kong; Guoliang Li; Siang Lin Loh; Wing-Kin Sung; Edison T Liu
Journal:  Mol Syst Biol       Date:  2011-08-30       Impact factor: 11.429

9.  GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility.

Authors:  Vasiliki Theodorou; Rory Stark; Suraj Menon; Jason S Carroll
Journal:  Genome Res       Date:  2012-11-21       Impact factor: 9.043

10.  Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.

Authors:  J L L Robinson; T E Hickey; A Y Warren; S L Vowler; T Carroll; A D Lamb; N Papoutsoglou; D E Neal; W D Tilley; J S Carroll
Journal:  Oncogene       Date:  2013-12-02       Impact factor: 9.867

View more
  11 in total

1.  Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1.

Authors:  Huan He; Dandan Song; Indranil Sinha; Bernd Hessling; Xidan Li; Lars-Arne Haldosen; Chunyan Zhao
Journal:  Oncogene       Date:  2019-04-23       Impact factor: 9.867

2.  Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer.

Authors:  Ze-Yi Zheng; Meenakshi Anurag; Jonathan T Lei; Jin Cao; Purba Singh; Jianheng Peng; Hilda Kennedy; Nhu-Chau Nguyen; Yue Chen; Philip Lavere; Jing Li; Xin-Hui Du; Burcu Cakar; Wei Song; Beom-Jun Kim; Jiejun Shi; Sinem Seker; Doug W Chan; Guo-Qiang Zhao; Xi Chen; Kimberly C Banks; Richard B Lanman; Maryam Nemati Shafaee; Xiang H-F Zhang; Suhas Vasaikar; Bing Zhang; Susan G Hilsenbeck; Wei Li; Charles E Foulds; Matthew J Ellis; Eric C Chang
Journal:  Cancer Cell       Date:  2020-03-05       Impact factor: 31.743

3.  Burkholderia Lethal Factor 1, a Novel Anti-Cancer Toxin, Demonstrates Selective Cytotoxicity in MYCN-Amplified Neuroblastoma Cells.

Authors:  Aleksander Rust; Sajid Shah; Guillaume M Hautbergue; Bazbek Davletov
Journal:  Toxins (Basel)       Date:  2018-06-27       Impact factor: 4.546

4.  ERα-related chromothripsis enhances concordant gene transcription on chromosome 17q11.1-q24.1 in luminal breast cancer.

Authors:  Chun-Lin Lin; Xi Tan; Meizhen Chen; Meena Kusi; Chia-Nung Hung; Chih-Wei Chou; Ya-Ting Hsu; Chiou-Miin Wang; Nameer Kirma; Chun-Liang Chen; Ching-Hung Lin; Kate I Lathrop; Richard Elledge; Virginia G Kaklamani; Kohzoh Mitsuya; Tim H-M Huang
Journal:  BMC Med Genomics       Date:  2020-05-14       Impact factor: 3.063

5.  Gene networks and transcriptional regulators associated with liver cancer development and progression.

Authors:  Tatiana Meier; Max Timm; Matteo Montani; Ludwig Wilkens
Journal:  BMC Med Genomics       Date:  2021-02-04       Impact factor: 3.063

6.  Epigenetic remodelling of enhancers in response to estrogen deprivation and re-stimulation.

Authors:  Athena Sklias; Andrea Halaburkova; Ludovica Vanzan; Nora Fernandez Jimenez; Cyrille Cuenin; Liacine Bouaoun; Vincent Cahais; Victor Ythier; Aurélie Sallé; Claire Renard; Geoffroy Durand; Florence Le Calvez-Kelm; Rita Khoueiry; Rabih Murr; Zdenko Herceg
Journal:  Nucleic Acids Res       Date:  2021-09-27       Impact factor: 16.971

7.  27-Hydroxycholesterol, The Estrogen Receptor Modulator, Alters DNA Methylation in Breast Cancer.

Authors:  Ravindran Vini; Arumugam Rajavelu; Sreeja Sreeharshan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-10       Impact factor: 5.555

8.  PA1 participates in the maintenance of blood-testis barrier integrity via cooperation with JUN in the Sertoli cells of mice.

Authors:  Bo Liu; Chao Liu; Binfang Ma; Ruidan Zhang; Zhiwei Zhao; Sai Xiao; Wanjun Cao; Yanjie Ma; Guozhang Zhu; Wei Li; Zhen Li
Journal:  Cell Biosci       Date:  2022-04-04       Impact factor: 7.133

9.  Widespread enhancer activation via ERα mediates estrogen response in vivo during uterine development.

Authors:  Wendy N Jefferson; H Karimi Kinyamu; Tianyuan Wang; Adam X Miranda; Elizabeth Padilla-Banks; Alisa A Suen; Carmen J Williams
Journal:  Nucleic Acids Res       Date:  2018-06-20       Impact factor: 16.971

10.  Targeting Pin1 by All-Trans Retinoic Acid (ATRA) Overcomes Tamoxifen Resistance in Breast Cancer via Multifactorial Mechanisms.

Authors:  Songyin Huang; Yang Chen; Zhi-Mei Liang; Na-Na Li; Yujie Liu; Yinghua Zhu; Dingzhun Liao; Xiao Zhen Zhou; Kun Ping Lu; Yandan Yao; Man-Li Luo
Journal:  Front Cell Dev Biol       Date:  2019-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.